Jan. 8 (UPI) -- Celgene Corp. has announced the acquisition of Impact Biomedicines, a company developing medication to combat bone marrow cancer.
Celgene, headquartered in Summit, N.J., will purchase San Diego-based Impact Biomedicines for $1.1 billion, with another $1.25 billion in later contingent payments based on regulatory approvals on other indicators of success.